✦ LIBER ✦

203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

✍ Scribed by B. Besse; K.D. Eaton; J.C. Soria; T.J. Lynch; V. Miller; K.K. Wong; C. Powell; S. Quinn; C. Zacharchuk; L.V. Sequist

Book ID: 119599358
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)72135-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vandetanib Versus Placebo in Patients Wi

Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

✍ Lee, J. S.; Hirsh, V.; Park, K.; Qin, S.; Blajman, C. R.; Perng, R.-P.; Chen, Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 193 KB

53LBA A phase I/IIa study of icotinib hy

53LBA A phase I/IIa study of icotinib hydrochloride (BPI-2009H), an oral epidermal growth factor receptor tyrosine kinases inhibitor, in patients with advanced non-small-cell lung cancer and other solid tumors

✍ Q. Zhao; J. Zhou; J. Shentu; L. Wu; N. Xu; F. Tan; Y. Wang; D. Yang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A phase I and pharmacokinetic study of d

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB